The University of Chicago Header Logo

Connection

Richard Schilsky to United States

Back to Details
This is a "connection" page, showing publications Richard Schilsky has written about United States.
Richard Schilsky
Connection Strength
2.044
United States
  1. Optimizing public-private partnerships to support clinical cancer research. J Natl Cancer Inst. 2025 Jul 01; 117(7):1305-1310.
    View in: PubMed
    Score: 0.092
  2. 'Strategic' development of precision cancer medicine in the United States. Mol Oncol. 2021 07; 15(7):1747-1749.
    View in: PubMed
    Score: 0.069
  3. The National Clinical Trials Network and the cooperative groups: The road not taken. Cancer. 2020 12 01; 126(23):5008-5013.
    View in: PubMed
    Score: 0.066
  4. Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey. JCO Oncol Pract. 2020 Jul; 16(7):417-421.
    View in: PubMed
    Score: 0.064
  5. Discrepancies in Financial Self-Disclosures and Open Payments Reporting Among Authors of Clinical Oncology Research Studies. J Clin Oncol. 2020 02 10; 38(5):480-487.
    View in: PubMed
    Score: 0.062
  6. State of Cancer Care in America: Reflections on an Inaugural Year. J Oncol Pract. 2019 04; 15(4):163-165.
    View in: PubMed
    Score: 0.059
  7. The State of Oncology Practice in America, 2018: Results of the ASCO Practice Census Survey. J Oncol Pract. 2018 07; 14(7):e412-e420.
    View in: PubMed
    Score: 0.056
  8. A New Look at the State of Cancer Care in America. J Oncol Pract. 2018 07; 14(7):397-399.
    View in: PubMed
    Score: 0.056
  9. Access versus evidence: The regulators' dilemma. Clin Trials. 2018 06; 15(3):240-242.
    View in: PubMed
    Score: 0.056
  10. Reply to S.D. Lucio. J Clin Oncol. 2018 07 10; 36(20):2127.
    View in: PubMed
    Score: 0.056
  11. Rationale, Opportunities, and Reality of Biosimilar Medications. N Engl J Med. 2018 May 24; 378(21):2036-2044.
    View in: PubMed
    Score: 0.056
  12. Hans Christian Andersen and the Value of New Cancer Treatments. J Natl Cancer Inst. 2018 05 01; 110(5):441-442.
    View in: PubMed
    Score: 0.056
  13. American Society of Clinical Oncology Statement: Biosimilars in Oncology. J Clin Oncol. 2018 04 20; 36(12):1260-1265.
    View in: PubMed
    Score: 0.055
  14. Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. J Clin Oncol. 2017 Nov 20; 35(33):3737-3744.
    View in: PubMed
    Score: 0.054
  15. Converging on the Value of Value Frameworks. J Clin Oncol. 2017 08 20; 35(24):2732-2734.
    View in: PubMed
    Score: 0.052
  16. Reply to J.P. Jansen, A. Messori et al, and H.S.L. Jim et al. J Clin Oncol. 2017 04 01; 35(10):1134.
    View in: PubMed
    Score: 0.051
  17. Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. J Clin Oncol. 2016 08 20; 34(24):2925-34.
    View in: PubMed
    Score: 0.049
  18. Gains Against Cancer, But Enter 'Financial Toxicity'. Manag Care. 2015 Oct; 24(10):46-7, 52-4.
    View in: PubMed
    Score: 0.047
  19. Integrating biomarkers in colorectal cancer trials in the West and China. Nat Rev Clin Oncol. 2015 Sep; 12(9):553-60.
    View in: PubMed
    Score: 0.045
  20. ASCO's initiative to define value in cancer care. Am J Manag Care. 2014 Aug; 20(11 Spec No.):E1.
    View in: PubMed
    Score: 0.043
  21. Drivers of change in cancer care. J Oncol Pract. 2014 Sep; 10(5):315-6.
    View in: PubMed
    Score: 0.043
  22. Progress against GI cancer during the American Society of Clinical Oncology's first 50 years. J Clin Oncol. 2014 May 20; 32(15):1521-30.
    View in: PubMed
    Score: 0.042
  23. American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol. 2013 Dec 01; 31(34):4362-70.
    View in: PubMed
    Score: 0.041
  24. Wither the cooperative groups? J Clin Oncol. 2014 Jan 20; 32(3):251-4.
    View in: PubMed
    Score: 0.040
  25. Reevaluating the accelerated approval process for oncology drugs. Clin Cancer Res. 2013 Jun 01; 19(11):2804-9.
    View in: PubMed
    Score: 0.039
  26. Publicly funded clinical trials and the future of cancer care. Oncologist. 2013; 18(2):232-8.
    View in: PubMed
    Score: 0.039
  27. Role of randomized phase III trials in an era of effective targeted therapies. Nat Rev Clin Oncol. 2011 Dec 06; 9(4):208-14.
    View in: PubMed
    Score: 0.036
  28. The next phase of chemoprevention research. Cancer Prev Res (Phila). 2011 Mar; 4(3):293-5.
    View in: PubMed
    Score: 0.034
  29. Data submission standards and evidence requirements. Oncologist. 2010; 15(5):488-91.
    View in: PubMed
    Score: 0.031
  30. Personalizing cancer care: American Society of Clinical Oncology presidential address 2009. J Clin Oncol. 2009 Aug 10; 27(23):3725-30.
    View in: PubMed
    Score: 0.030
  31. The Translational Research Working Group developmental pathway for anticancer agents (drugs or biologics). Clin Cancer Res. 2008 Sep 15; 14(18):5685-91.
    View in: PubMed
    Score: 0.029
  32. American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites. J Clin Oncol. 2008 May 20; 26(15):2562-7.
    View in: PubMed
    Score: 0.028
  33. The role of cooperative groups in cancer clinical trials. Cancer Treat Res. 2007; 132:111-29.
    View in: PubMed
    Score: 0.025
  34. A concise history of the cancer and leukemia group B. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3553s-5s.
    View in: PubMed
    Score: 0.024
  35. Hurry up and wait: is accelerated approval of new cancer drugs in the best interests of cancer patients? J Clin Oncol. 2003 Oct 15; 21(20):3718-20.
    View in: PubMed
    Score: 0.020
  36. End points in cancer clinical trials and the drug approval process. Clin Cancer Res. 2002 Apr; 8(4):935-8.
    View in: PubMed
    Score: 0.018
  37. Use of Biosimilar Medications in Oncology. JCO Oncol Pract. 2022 Mar; 18(3):177-186.
    View in: PubMed
    Score: 0.018
  38. Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO Registry. JCO Oncol Pract. 2022 04; 18(4):e426-e441.
    View in: PubMed
    Score: 0.018
  39. Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer. J Clin Oncol. 2021 04 01; 39(10):1165-1184.
    View in: PubMed
    Score: 0.017
  40. Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs. Oncologist. 2020 03; 25(3):e405-e411.
    View in: PubMed
    Score: 0.016
  41. Effect of Public Deliberation on Patient Attitudes Regarding Consent and Data Use in a Learning Health Care System for Oncology. J Clin Oncol. 2019 12 01; 37(34):3203-3211.
    View in: PubMed
    Score: 0.015
  42. Improving Cancer Diagnosis and Care: Patient Access to Oncologic Imaging Expertise. J Clin Oncol. 2019 07 10; 37(20):1690-1694.
    View in: PubMed
    Score: 0.015
  43. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol. 2018 06 01; 36(16):1631-1641.
    View in: PubMed
    Score: 0.014
  44. Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement. J Clin Oncol. 2018 02 20; 36(6):617-623.
    View in: PubMed
    Score: 0.014
  45. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2017 06 20; 317(23):2392-2401.
    View in: PubMed
    Score: 0.013
  46. Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2017 04 20; 35(12):1341-1367.
    View in: PubMed
    Score: 0.013
  47. Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012. J Clin Oncol. 2016 11 20; 34(33):3992-3999.
    View in: PubMed
    Score: 0.012
  48. Transformation of Health Care - Perspectives of Opinion Leaders. Semin Oncol Nurs. 2016 05; 32(2):172-82.
    View in: PubMed
    Score: 0.012
  49. Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. J Natl Cancer Inst. 2015 Nov; 107(11).
    View in: PubMed
    Score: 0.012
  50. Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study. J Clin Oncol. 1995 Sep; 13(9):2230-7.
    View in: PubMed
    Score: 0.012
  51. American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. J Clin Oncol. 2015 Aug 10; 33(23):2563-77.
    View in: PubMed
    Score: 0.011
  52. Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. Ann Oncol. 2015 Aug; 26(8):1791-8.
    View in: PubMed
    Score: 0.011
  53. Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study. J Clin Oncol. 1995 Mar; 13(3):741-7.
    View in: PubMed
    Score: 0.011
  54. Leveraging biospecimen resources for discovery or validation of markers for early cancer detection. J Natl Cancer Inst. 2015 Apr; 107(4).
    View in: PubMed
    Score: 0.011
  55. Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2015 Mar 01; 33(7):786-809.
    View in: PubMed
    Score: 0.011
  56. Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802). J Natl Cancer Inst. 2015 Jan; 107(1):336.
    View in: PubMed
    Score: 0.011
  57. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014 Apr 20; 32(12):1277-80.
    View in: PubMed
    Score: 0.010
  58. Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists. J Clin Oncol. 2013 Mar 20; 31(9):1134-9.
    View in: PubMed
    Score: 0.010
  59. Biological, clinical, and psychosocial correlates at the interface of cancer and aging research. J Natl Cancer Inst. 2012 Apr 18; 104(8):581-9.
    View in: PubMed
    Score: 0.009
  60. Patient advocates' role in clinical trials: perspectives from Cancer and Leukemia Group B investigators and advocates. Cancer. 2012 Oct 01; 118(19):4801-5.
    View in: PubMed
    Score: 0.009
  61. WIN Consortium--challenges and advances. Nat Rev Clin Oncol. 2011 Mar; 8(3):133-4.
    View in: PubMed
    Score: 0.008
  62. Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst. 2010 Nov 17; 102(22):1698-705.
    View in: PubMed
    Score: 0.008
  63. Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2009 Feb 10; 27(5):812-26.
    View in: PubMed
    Score: 0.007
  64. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008 Nov 01; 26(31):5043-51.
    View in: PubMed
    Score: 0.007
  65. Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants. Med Care. 2008 Mar; 46(3):303-8.
    View in: PubMed
    Score: 0.007
  66. Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2008 Jan 10; 26(2):313-25.
    View in: PubMed
    Score: 0.007
  67. Drug safety and drug efficacy: two sides of the same coin. Clin Cancer Res. 2007 May 01; 13(9):2533-4.
    View in: PubMed
    Score: 0.006
  68. Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst. 2006 Sep 20; 98(18):1335-8.
    View in: PubMed
    Score: 0.006
  69. Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. J Natl Cancer Inst. 2005 Jul 20; 97(14):1080-3.
    View in: PubMed
    Score: 0.006
  70. Oncology physician and nurse practices and attitudes regarding offering clinical trial results to study participants. J Natl Cancer Inst. 2004 Apr 21; 96(8):629-32.
    View in: PubMed
    Score: 0.005
  71. Construct validity of medicare chemotherapy claims: the case of 5FU. Med Care. 2002 Mar; 40(3):201-11.
    View in: PubMed
    Score: 0.005
  72. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst. 1993 Oct 20; 85(20):1637-43.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.